1990PubMedRequires access

[Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].

von Pawel J, H. Wilke, Dominic Vallée, H Dimbeck, Hans‐Joachim Schmoll

Open publisher page 1 citations

Abstract

The remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.

About this research paper

What this paper is about

The remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.

Key concepts: Etoposide, Vincristine, Medicine, Oncology, Cisplatin, Internal medicine, Chemotherapy, Cyclophosphamide

Back to paper searchBrowse research topicsOriginal source
[Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)]. — Research Paper | ScholarLens